Publications by authors named "Luis Feliz"

Claim this Profile
P
Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.
Daniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, Sjors M Kas, Frank Rolfs

Nature· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma.
Ghassan K Abou-Alfa, Kristen Bibeau, Nikolaus Schultz, Amin Yaqubie, Brittanie Millang

Target Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.
Daniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, Sjors M Kas, Frank Rolfs

Nature· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling.
Ian M Silverman, Meijuan Li, Karthikeyan Murugesan, Melanie A Krook, Milind M Javle, Luis Feliz

J Mol Diagn· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progression-Free Survival in Patients With Cholangiocarcinoma With or Without Alterations: A FIGHT-202 Post Hoc Analysis of Prior Systemic Therapy Response.
Kristen Bibeau, Luis Féliz, Christine F Lihou, Haobo Ren, Ghassan K Abou-Alfa

JCO Precis Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinicogenomic Analysis of -Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib.
Ian M Silverman, Antoine Hollebecque, Luc Friboulet, Sherry Owens, Robert C Newton

Cancer Discov· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with rearrangements.
Tanios S Bekaii-Saab, Juan W Valle, Eric Van Cutsem, Lorenza Rimassa, Junji Furuse

Future Oncol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Ghassan K Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, Gina Vaccaro, Davide Melisi

Lancet Oncol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative study on the use of three different near infrared spectroscopy recording methodologies for varietal discrimination of walnuts.
Julio Nogales-Bueno, Luis Feliz, Berta Baca-Bocanegra, José Miguel Hernández-Hierro, Francisco José Heredia

Talanta· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant therapy sparing in rectal cancer achieving complete response after chemoradiation.
Xabier García-Albéniz, Rosa Gallego, Ralf Dieter Hofheinz, Gloria Fernández-Esparrach, Juan Ramón Ayuso-Colella, Luis Feliz

World J Gastroenterol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of patients treated with palliative weekly paclitaxel plus cetuximab in recurrent head and neck cancer after failure of platinum-based therapy.
Aaron E Sosa, Juan J Grau, Luis Feliz, Verónica Pereira, Diego Alcaraz

Eur Arch Otorhinolaryngol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-vascular endothelial growth factor therapy in the era of personalized medicine.
Luis R Féliz, Apostolia M Tsimberidou

Cancer Chemother Pharmacol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis